Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...

Discover what were the top biotech deals that were signed in March 2026. From small molecules to antibodies, M&A activity was high.

The average one-year price target for Nautilus Biotechnology (NasdaqCM:NAUT) has been revised to $4.08 / share. This is an increase of 60.00% from the prior estimate of $2.55 dated February 21, 2026.

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma. We’re keeping the same guidelines used for last ...

Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...

The average one-year price target for Vir Biotechnology (NasdaqGS:VIR) has been revised to $20.74 / share. This is an increase of 26.10% from the prior estimate of $16.45 dated February 21, 2026. The ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

Biotech executives, investors, and R&D leaders all face the same burning question in 2026: How do we scale breakthroughs from ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) today announced that following an application to The Stock Exchange of Hong Kong Limited (the 'Stock ...